Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174905 | PMC |
| http://dx.doi.org/10.1136/bcr-2016-218652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells.
Stem Cell Res Ther
November 2020
Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 2015 Uppergate Drive, Atlanta, GA, 30322, USA.
Background: Treatment-induced cardiotoxicity is a leading noncancer-related cause of acute and late onset morbidity and mortality in cancer patients on antineoplastic drugs such as melphalan-increasing clinical case reports have documented that it could induce cardiotoxicity including severe arrhythmias and heart failure. As the mechanism by which melphalan impairs cardiac cells remains poorly understood, here, we aimed to use cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) to investigate the cellular and molecular mechanisms of melphalan-induced cardiotoxicity.
Methods: hiPSC-CMs were generated and treated with clinically relevant doses of melphalan.
Chemotherapy-induced cardiotoxicity is a known condition, however, bortezomib and melphalan do not typically cause cardiotoxicity. With the rise in the use of newer chemotherapeutic agents, it is important to identify and understand the cardiac implications of chemotherapeutic agents. We present a case of a 70-year-old female with no known significant cardiac history presenting with partially reversible cardiomyopathy with initial presentation only being as sinus tachycardia.
View Article and Find Full Text PDFMelphalan-induced cardiotoxicity: ventricular arrhythmias.
BMJ Case Rep
December 2016
Department of Internal Medicine (Clinical Hematology Division), Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Melphalan-induced supraventricular tachycardia: incidence and risk factors.
Clin Cardiol
June 2011
Department of Medicine, Division of Cardiology, University of South Florida, Tampa, Florida 33606, USA.
Background: Cardiotoxicity of aggressive chemotherapeutic regimens includes cardiomyopathy and arrhythmias. Although cardiomyopathy is a well-recognized entity, arrhythmias are poorly studied.
Hypothesis: Certain chemotherapeutic regimes are associated with supraventricular arrhythmias, particularly atrial fibrillation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!